ANN ARBOR, Mich., Nov. 24 /PRNewswire/ -- Terumo Heart, Inc. is pleased to announce the appointment of William Pinon to the position of Chief Executive Officer (C.E.O.) and President, effective immediately. "With its innovative mag-lev technology, Terumo Heart is positioned for a strong leadership role in the future treatment of heart failure. I am excited to lead the acceleration of enrollment in the DuraHeart U.S. Pivotal trials in up to 40 clinical sites, and further capitalize on the commercial potential for DuraHeart's CE Mark in Europe," Mr. Pinon commented. Chisato Nojiri, M.D. Ph.D. will continue to serve as Chairperson of the Board and Chief Medical Officer of Terumo Heart, Inc. Dr. Nojiri has been instrumental in bringing the product from its very early development phase through commercialization in Europe, to the start of the U.S. Pivotal Clinical Trial and recent completion of the Japanese Clinical Trial patient enrollment. Dr. Nojiri will continue her global clinical and scientific focus and leadership.
"With the expansion of our U.S. clinical sites, Terumo Heart is experiencing rapid growth. Mr. Pinon's proven track record in the cardiovascular industry and extensive sales and operational experience, are ideally suited to lead our commercialization efforts in the U.S. and continued growth in Europe," said Dr. Nojiri.
Most recently, Mr. Pinon was C.E.O. of Bioheart, a biotechnology company
focused on the development of heart failure therapies and devices. Prior to
Bioheart, Mr. Pinon held a variety of positions with Johnson & Johnson
including Worldwide Vice President of Sales and Marketing at Cordis
Corporation where he oversaw the cardiovascular business including the market
leading drug eluting stent, CYPHER (TM). Mr. Pinon received a bachelor's
degree in biology from the
Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with
|SOURCE Terumo Heart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved